A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Baricitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms BRAVE I
- Sponsors Eli Lilly and Company
- 16 Apr 2019 Planned End Date changed from 16 Feb 2021 to 21 May 2021.
- 16 Apr 2019 Planned primary completion date changed from 16 Feb 2021 to 21 May 2021.
- 10 Aug 2018 Status changed from not yet recruiting to recruiting.